The Diagnostics and Spatial Biology segment's revenues were up 2 percent compared to the prior-year quarter, while Protein Sciences revenues rose 6 percent.

The firm reported that its total revenues jumped 9 percent in Q2, but it lowered the low end of its EPS guidance to account for the uncertainty of tariffs and other trade barriers.

Kuppusamy noted that Quest does offer testing, and advanced diagnostic testing in particular, through its Global Diagnostics ...

The firm brought in revenues of $29.9 million in Q1, down 45 percent from $54.1 million in Q1 2024 but narrowly beating the consensus Wall Street estimate of $29.6 million.

The firm's non-respiratory revenues slid a fraction of 1 percent year over year, while its respiratory revenues were down 13 percent.

The offering consisted of 10,156,250 shares of common stock or pre-funded warrants, together with warrants to purchase up to 15,234,375 shares of common stock.

The firm reported that its total revenues jumped 9 percent in Q2, but it lowered the low end of its EPS guidance to account for the uncertainty of tariffs and other trade barriers.

The Diagnostics and Spatial Biology segment's revenues were up 2 percent compared to the prior-year quarter, while Protein Sciences revenues rose 6 percent.

The Diagnostics and Spatial Biology segment's revenues were up 2 percent compared to the prior-year quarter, while Protein Sciences revenues rose 6 percent.

The companies are developing a rapid, at-home colorectal cancer test that uses interstitial fluid as a sample type.

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

The firm reported growth across its immunodiagnostics and molecular diagnostics businesses as well as contributions from the firm's licensed technologies business.